icon-    folder.gif   Conference Reports for NATAP  
 
  (APASL) 25th Conference of the Asian Pacific
Association for the Study of the Liver
Feb 20-24 2016, Tokyo, Japan

Back grey_arrow_rt.gif
 
 
 
Daclatasvir/Asunaprevir/Beclabuvir
Fixed-Dose Combination in Treatment-Naive and
Interferon-Experienced Japanese Patients With
HCV Genotype 1 Infection: UNITY-3 Study

 
 
  Reported by Jules Levin
25th Conference of the Asian Pacific Association for the Study of the Liver: APASL 2016, Tokyo, Japan
 
Chayama K,1 Toyota J,2 Karino Y,2 Suzuki F,3 Ikeda F,4 Ido A,5 Tanaka K,6 Takaguchi K,7 Naganuma A,8 Tomita E,9 Fujiyama S,10 Inada Y,11 Yoshiji H,12 Watanabe H,13 Ishikawa H,13 Hu W,14 McPhee F,14 Linaberry M,14 Yin PD,14 Swenson ES,14 Kumada H3
 
1Hiroshima University, Hiroshima, Japan; 2Sapporo-Kosei General Hospital, Sapporo, Japan; 3Toranomon Hospital, Tokyo, Japan; 4Okayama University, Okayama, Japan; 5Kagoshima University, Kagoshima, Japan; 6Yokohama City University Medical Center, Yokohama, Japan;
7Kagawa Prefectural Central Hospital, Takamatsu City, Japan; 8Takasaki General Medical Center,
Takasaki, Japan; 9Gifu Municipal Hospital, Gifu, Japan; 10Kumamoto Shinto General Hospital, Kumamoto, Japan; 11Miyazaki Medical Center Hospital, Miyazaki, Japan; 12Nara Medical University, Kashihara, Japan;
13Bristol-Myers K.K., Tokyo, Japan; 14Bristol-Myers Squibb, Princeton, NJ, USA

APSAL1

APSAL2

APSAL3

APSAL4

APSAL5

APSAL6